TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01418053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caraway oil
Description: essential oil, Carum carvi, 2% dissolved in olive oil, 1 teaspoon with caraway oil used externally as inunction together with a hot cataplasm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olive oil
Description: 1 teaspoon with caraway oil used externally as inunction together with a hot or cold cataplasm as assigned

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olive oil
Description: 1 teaspoon with caraway oil used externally as inunction together with a hot or cold cataplasm as assigned
Study: NCT00935519

Intervention type: DEVICE
Group type: OTHER
Intervention: 4th generation ceramic bearing composite ceramic bearing
Description: THA with use of the new alumina-zirconia(4th generation ceramic bearing) composite ceramic bearing at a minimum of 10 years follow-up.
Study: NCT02547116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Addition of Rifampin to standard anti-Staphylococcal treatment regimen
Study: NCT04253444

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: slow deep breathing
Description: Participants in this arm will be asked to do slow deep breathing (4 seconds inhalation and 6 seconds exhalation) for 10 minutes twice a day during the study period.
Study: NCT01575197

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Rotavirus Vaccine
Description: Rotavirus vaccine will be administered concomitantly with other routine Expanded Programme on Immunization (EPI) vaccinations at 6 \& 10 weeks of age, 10 \& 14 weeks of age, or 6, 10, \& 14 weeks of age, depending on study arm assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Rotavirus Vaccine
Description: Rotavirus vaccine will be administered concomitantly with other routine Expanded Programme on Immunization (EPI) vaccinations at 6 \& 10 weeks of age, 10 \& 14 weeks of age, or 6, 10, \& 14 weeks of age, depending on study arm assignment.
Study: NCT02189109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVX-108
Description: 0.2% emulsion administered i.v.
Study: NCT02895217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ergocycle
Study: NCT01575197

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Rotavirus Vaccine
Description: Rotavirus vaccine will be administered concomitantly with other routine Expanded Programme on Immunization (EPI) vaccinations at 6 \& 10 weeks of age, 10 \& 14 weeks of age, or 6, 10, \& 14 weeks of age, depending on study arm assignment.
Study: NCT03907800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 2, weekly, 3 weeks on 1 week off, applicated for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: In case of HER2-positive, patients receive Herceptin weekly during all cycles.
Study: NCT00789763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 300 mg/m2/one per week, i.v., during 5 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 1.8 Gy/day 5 days per week during 5 weeks (total dose 45Gy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 200-800 mg/day p.o. during 5 weeks
Study: NCT00286819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: the FEC75 and 95 regimen
Description: Fluorouracil 500mg/m2 by i.v. bolus or infusion. Epirubicin 75mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion. All three drugs will be administered intravenously on Day 1 of each 14-day cycles.~Arm B: the FEC90 regimen will be given at the following doses:~Fluorouracil 500mg/m2 by i.v. bolus or infusion.Epirubicin 90mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion.~All three drugs will be administered intravenously on Day 1 of each 14-day cycles.~Pegfilgrastim fixed dose of 6mg as a single subcutaneous injection will be given in both arms on Day 2 of each cycle.~Six cycles of adjuvant chemotherapy will be administered in both arms (A + B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: the FEC75 and 95 regimen
Description: Fluorouracil 500mg/m2 by i.v. bolus or infusion. Epirubicin 75mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion. All three drugs will be administered intravenously on Day 1 of each 14-day cycles.~Arm B: the FEC90 regimen will be given at the following doses:~Fluorouracil 500mg/m2 by i.v. bolus or infusion.Epirubicin 90mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion.~All three drugs will be administered intravenously on Day 1 of each 14-day cycles.~Pegfilgrastim fixed dose of 6mg as a single subcutaneous injection will be given in both arms on Day 2 of each cycle.~Six cycles of adjuvant chemotherapy will be administered in both arms (A + B
Study: NCT00553592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicifadine
Description: 600mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bicifadine
Description: placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicifadine
Description: 1200 mg
Study: NCT02343757

Intervention type: DEVICE
Group type: OTHER
Intervention: PET/MRI
Study: NCT01626963

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-port access surgery
Description: Surgery carried out through a single incision laparoscopic approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Laparoscopic Access
Description: Surgery through standard multiport laparoscopic approach
Study: NCT04080609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dorzagliatin
Description: GKA currently under clinical development
Study: NCT01615887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisdexamfetamine sulfate
Description: 30mg lisdexamfetamine OD, increased to 70mg OD over 4 weeks and continued on 70mg OD for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: sugar pill
Study: NCT04963387

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration
Description: Balance and muscle strengthening exercises with whole-body vibration, strengthening exercise included straight leg raise with weights, and balance training including walking heel to toe for 20 steps. In this study frequency of 30Hz (4 weeks), with 0.9 mm vertical displacement was used.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance and Strengthening exercise
Description: Balance and strengthening exercises includes straight leg raise with weights 10 reps. and tandem walk 20 steps 3 days in week for 4 weeks
Study: NCT02612454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Weight-tiered dosing administered subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Weight-tiered dosing administered subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Weight-tiered dosing administered subcutaneous (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Weight-tiered dosing administered subcutaneous (SC)
Study: NCT01364324

Intervention type: DRUG
Intervention: standard first line anti-TB drugs
Description: We will perform pharmacokinetic study in gastrectomy and non-gastrectomy group, to evaluate the effect of gastrectomy on pharmacokinetic profile of first-line anti-TB drugs in patients with TB

Intervention type: DRUG
Intervention: standard first line anti-TB drugs
Description: We will perform pharmacokinetic study in gastrectomy and non-gastrectomy group, to evaluate the effect of gastrectomy on pharmacokinetic profile of first-line anti-TB drugs in patients with TB
Study: NCT00726102

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Meat
Description: 2 0z of locally available meat per day
Study: NCT02933944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Study: NCT04253444

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: sham breathing
Description: Participants in this arm will be asked to do sham breathing for 10 minutes twice a day during the study period.
Study: NCT01439633

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MGH OFDI marking
Description: Imaging of esophagus with OFDI system
Study: NCT02040389

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Picture book
Description: Arm with showing and explaining for parents about perioperative typical surgery site/wound view by study's team

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard preoperative education
Description: Arm with standard, verbal explaining for a parents about perioperative site/wound view
Study: NCT01082302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyphenon E (Veregen) 15% ointment
Description: 3 times daily application on genital and perianal warts over 7 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Green Tea Beverage with defined catechin content
Description: 3 times daily oral intake over 7 days
Study: NCT01578161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: There are four groups accoding to dosage of dexmedetomidine. Dexmedetomidine 0.25 microg.kg(-1),(group D0.25), dexmedetomidine 0.5 microg.kg(-1),(Group D0.5), dexmedetomidine 1 microg.kg(-1) (Group D 1) and normal saline(group P) is administered ivs. for 10mins when we are inducing each patient.
Study: NCT00469274

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic PEP
Description: Azithromycin 1000mg po x 1, then 500mg po Q day for 4 days; TMP-SMX DS one BID for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic PEP
Description: TMP-SMX DS po BID for 14 days
Study: NCT02656732

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: amnion chorion allograft membrane
Description: Biologic Amnion chorion allograft membrane derived from placenta of a donor pregnant subject.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: coronally advanced flap with the subepithelial connective tissue graft
Description: coronally advanced flap with the placement of subepithelial connective tissue graft harvested from the palate
Study: NCT01929005

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Care
Description: Patients will receive comprehensive medical care from their CCP in clinic and the hospital. For most patients, the ambulatory care provided by the CCP will be in our onsite medicine clinic, but for some patients with subspecialty needs the CCP may be a specialist who will care for the patient in a nearby ambulatory setting (e.g., nursing home, dialysis facility). The CCPs will also supervise the nurses, pharmacists, social workers, and others who are part of the multi-disciplinary care team. Daytime inpatient care will be provided by CCPs in conjunction with our inpatient advanced practice nurses (APNs). These APNs now work with our hospitalists, so they are experienced providing hospital care.
Study: NCT03719612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEFINITY®
Description: All subjects will receive a single dose of DEFINITY®
Study: NCT03533296

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positive end expiratory pressure (PEEP)
Description: The different levels of PEEP, 5 cmH2O, 8 cmH2O and 12 cmH2O, are applied serially. Mean respiratory compliance and intratidal compliance-volume profile are evaluated.
Study: NCT03361163

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: emm75 Streptococcus pyogenes (GAS M75, strain 611024)
Description: Direct oropharyngeal application by swab following immersion in a solution containing a specified concentration (dose) of GAS M75.
Study: NCT00968214

Intervention type: GENETIC
Intervention: polymorphism analysis

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Study: NCT02430623

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Irreversible Electroportion For Unresectable Urinary Bladder Neoplasms guide with ultrasound or/and CT.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife
Study: NCT01507012

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berry Polyphenols

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berry Polyphenols

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control containing sugar and artificial flavouring.
Study: NCT00143182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: Asenapine , 9 weeks
Study: NCT00143182

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Olanzapine, 9 weeks
Study: NCT04882618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: indocyanine green application during LRRP to detect positive lymph nodes. ICG will be injected to prostate lobes via csytoscopy
Study: NCT00705484

Intervention type: BIOLOGICAL
Intervention: infliximab
Description: The treating physician will determine the treatment regimen and dose of Remicade.

Intervention type: DRUG
Intervention: Standard Therapy
Description: The standard therapy group will consist of participants receiving a treatment regimen that does not include Remicade. The treatment of each standard therapy participant will be left to the discretion of the treating physician and may change during the course of a participant's participation in the registry.
Study: NCT01850628

Intervention type: DRUG
Intervention: Paclitaxel

Intervention type: BIOLOGICAL
Intervention: trastuzumab

Intervention type: BIOLOGICAL
Intervention: pertuzumab
Study: NCT01610570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mithramycin
Description: Phase I Portion: Mithramycin will be administered in escalating doses to children and adolescents intravenously over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression. If maximum tolerated dose (MTD) in this Phase differs from the recommended adult dose for Phase II, the protocol will be amended. Using a Simon two stage design, mithramycin will be administered intravenously at 17.5 microgram/kg over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression to children and adults with Ewing sarcoma with Ewings sarcoma - friend leukemia integration 1 transcription factor (EWS-FLI1) fusion transcript Both Phases will enroll patients simultaneously. Phase II Portion: mithramycin will be administered intravenously at 17.5 microgram/kg over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression to children and adults.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mithramycin
Description: Phase I Portion: Mithramycin will be administered in escalating doses to children and adolescents intravenously over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression. If maximum tolerated dose (MTD) in this Phase differs from the recommended adult dose for Phase II, the protocol will be amended. Using a Simon two stage design, mithramycin will be administered intravenously at 17.5 microgram/kg over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression to children and adults with Ewing sarcoma with Ewings sarcoma - friend leukemia integration 1 transcription factor (EWS-FLI1) fusion transcript Both Phases will enroll patients simultaneously. Phase II Portion: mithramycin will be administered intravenously at 17.5 microgram/kg over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression to children and adults.
Study: NCT01578161

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline
Description: Placebo,Normal saline 10ml ivs. for 10min.
Study: NCT04577781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3970
Description: GLPG3970 powder and solvent for oral solution to be reconstituted prior to use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo powder and solvent for oral solution to be reconstituted prior to use.
Study: NCT02348203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given aspirin placebo PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Administration
Description: Given zileuton placebo PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zileuton
Description: Given PO
Study: NCT03025126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimedial Rehabilitation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care program
Description: Usual care at home program according to healthcare professional's advice
Study: NCT01464879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Gel (FE 999303)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Gel (FE 999303)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Gel (FE 999303)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Gel (FE 999303)
Study: NCT00617864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Albumin Infusion
Description: Group will receive single infusion of albumin at the time of oocyte retrieval.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Infusion
Description: Group will receive single infusion of saline at the time of oocyte retrieval.
Study: NCT00839969

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Cystoscopy
Description: Saline cystoscopy under general anaesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cystoscopy and urethral dilatation
Description: Saline cystoscopy and urethral dilatation (using Hegar dilators) under general anaesthesia
Study: NCT05104827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complementary Integrative Medicine
Description: 30-minute individually tailored integrative medicine care, including acupuncture, acupressure, reflexology, movement therapies like QiGong or Feldenkrais as well as Anthroposophic Medicine and mind-body treatments.
Study: NCT02455739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chewing gum
Description: postoperative gum chewing to improve gastrointestinal function
Study: NCT02421094

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GR-MD-02
Description: GM-MD-02 active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03937479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium
Description: Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 0.375 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium
Description: Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 0.75 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium
Description: Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 1.5 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium
Description: Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 3.0 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropium
Description: Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● Placebo twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication.
Study: NCT01880957

Intervention type: DRUG
Group type: OTHER
Intervention: Lithium

Intervention type: DRUG
Group type: OTHER
Intervention: Lamotrigine
Study: NCT03430167

Intervention type: OTHER
Group type: OTHER
Intervention: home therapy
Description: Patients will be given a set of instructions for completing home therapy for range of motion and strengthening
Study: NCT03203616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KADCYLA 160 MG Injection
Description: Kadcyla 160Mg Powder for Injection: 3.6 mg/kg iv every 3 weeks
Study: NCT02503657

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tipelukast
Description: A novel, orally bioavailable small molecule compound that demonstrates anti-inflammatory and anti-fibrotic activity

Intervention type: DRUG
Group type: OTHER
Intervention: tipelukast
Description: A novel, orally bioavailable small molecule compound that demonstrates anti-inflammatory and anti-fibrotic activity

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Excipients of MN-001/tipelukast
Study: NCT00303901

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryosurgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Study: NCT04158492

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: real-time multiplex PCR
Description: Patients will be randomly assigned to receive experimental diagnosis (comprehensive molecular testing added to routine microbiological testing) AND standard diagnosis microbiological procedures
Study: NCT03430167

Intervention type: OTHER
Group type: OTHER
Intervention: formal therapy
Description: Patients will be sent to physical therapist for formal treatment to regain range of motion and strengthening exercises